David Kull - Rockwell Medical Principal Accounting Officer
| RMTI Stock | USD 2.29 0.07 3.15% |
Executive
Mr. David Kull is a Principal Accounting Officer of Rockwell Medical, Inc. He has served as the Companys Controller since 2007. Mr. Kull is a certified public accountant. In connection with his appointment in this role, Mr. Kull will continue to serve as Controller of the Company and will continue to oversee the Companys accounting department and the preparation of the Companys financial statements. since 2018.
| Age | 56 |
| Tenure | 6 years |
| Address | 30142 South Wixom road, Wixom, MI, United States, 48393 |
| Phone | 248 960 9009 |
| Web | https://www.rockwellmed.com |
Rockwell Medical Management Efficiency
The company has return on total asset (ROA) of (0.0425) % which means that it has lost $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.289) %, meaning that it created substantial loss on money invested by shareholders. Rockwell Medical's management efficiency ratios could be used to measure how well Rockwell Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.22. The current Return On Capital Employed is estimated to decrease to -0.2. As of now, Rockwell Medical's Total Current Assets are increasing as compared to previous years. The Rockwell Medical's current Intangible Assets is estimated to increase to about 13 M, while Total Assets are projected to decrease to under 37.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jon MBA | Biofrontera | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
| Daniel JD | Biofrontera | N/A | |
| Chris Bitterman | Cumberland Pharmaceuticals | 59 | |
| Mark CPA | Evoke Pharma | 47 | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Jose Vieira | Procaps Group SA | 58 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| YatPui Au | Regencell Bioscience Holdings | 50 | |
| Chaime Orlev | Kamada | 54 | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Luigi MD | Incannex Healthcare Ltd | N/A | |
| DMD MD | Evoke Pharma | 76 | |
| MBA MD | Aquestive Therapeutics | 66 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Shavit Beladev | Kamada | N/A | |
| Carl MD | Aquestive Therapeutics | 54 | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Camilo Camacho | Procaps Group SA | 50 | |
| Todd Anthony | Cumberland Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.0425 |
Rockwell Medical Leadership Team
Elected by the shareholders, the Rockwell Medical's board of directors comprises two types of representatives: Rockwell Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rockwell. The board's role is to monitor Rockwell Medical's management team and ensure that shareholders' interests are well served. Rockwell Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rockwell Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Kull, Principal Accounting Officer | ||
| Paul McGarry, Principal Accounting Officer, Vice President Corporate Controller | ||
| Jason Finkelstein, Investor Representative | ||
| Megan Timmins, Chief VP | ||
| Mark Strobeck, CEO President | ||
| Marc MD, Chief Officer | ||
| Jesse Neri, Senior Finance | ||
| James McCarthy, Senior Development | ||
| Timothy Chole, Senior Marketing | ||
| Heather Hunter, Senior Officer |
Rockwell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rockwell Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.0425 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 67.65 M | ||||
| Shares Outstanding | 32.32 M | ||||
| Shares Owned By Insiders | 12.33 % | ||||
| Shares Owned By Institutions | 21.26 % | ||||
| Number Of Shares Shorted | 1.12 M | ||||
| Price To Earning | (14.72) X |
Currently Active Assets on Macroaxis
When determining whether Rockwell Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rockwell Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rockwell Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rockwell Medical Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rockwell Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Rockwell Stock please use our How to Invest in Rockwell Medical guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rockwell Medical. If investors know Rockwell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rockwell Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 3.041 | Quarterly Revenue Growth 0.429 | Return On Assets (0.04) | Return On Equity (0.29) |
The market value of Rockwell Medical is measured differently than its book value, which is the value of Rockwell that is recorded on the company's balance sheet. Investors also form their own opinion of Rockwell Medical's value that differs from its market value or its book value, called intrinsic value, which is Rockwell Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rockwell Medical's market value can be influenced by many factors that don't directly affect Rockwell Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rockwell Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rockwell Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rockwell Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.